With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results